Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NeoAg-mBRAF · BRAF 585

Vaccine (Peptide vaccine) · Immune activation, directed at BRAF V600E mutant peptide

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is NeoAg-mBRAF?

NeoAg-mBRAF is a peptide vaccine made of the BRAF V600E mutant peptide spanning residues 586-614, with an added N-terminal histidine. It is designed to present this mutation-specific antigen to the immune system. It is studied in melanoma, including ocular and uveal melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BRAF 585
Drug type
Vaccine (Peptide vaccine)
Targets
BRAF V600E mutant peptide (antigen)
Mechanism
Immune activation, directed at BRAF V600E mutant peptide
Therapy area
Oncology
In trials of
CLDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04364230 Phase 1/2 Melanoma Completed CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MelanomaOcular MelanomaUveal Melanoma

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.